Clinical Trials
Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma
Disease Type: Melanoma
A phase 3 study of fixed dose combinations of fianlimab and cemiplimab versus relatlimab and nivolumab in participants with unresectable or metastatic melanoma.
Locations
Alleghany , Blacksburg , Roanoke , Salem , Wytheville